Citations

Clear

48 citation(s) found for "Sauer, JS".

Evaluating temperature gradients across the posterior left atrium with radiofrequency ablation
Sandhu, Amneet , Holman, Blair , Lammers, Steven R. , Cerbin, Lukasz , Barrett, Christopher , Sabzwari, Rafay , Garg, Lohit , Zipse, Matthew M. , Tumolo, Alexis Z. , Alvensleben, Johannes von, West, John J., Varosy, Paul D. , Nguyen, Duy T. , Sauer, William H. , Sauer, William H. , Sauer, William H , Tzou, Wendy , Aleong, Ryan G. , Alvensleben, Johannes C. von , Rosenberg, Michael A. , West, John J. , Tzou, Wendy S.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 22, 2023 | Volume: 34 | Issue: 4 | Pages: 880-887

10.1111/jce.15826 | PMID 36682068 Get It

AbstractIntroductionEsophageal injury is a well‐known complication associated with catheter ablation. Though novel methods to mitigate esophageal injury have been developed, few studies have evaluated temperature gradients with catheter ablation across the posterior wall of the left atrium, interstitium, and esophagus.MethodsTo investigate temperature gradients across the tissue, we developed a porcine heart–esophageal model to perform ex vivo catheter ablation on the posterior wall of the left atrium (LA), with juxtaposed interstitial tissue and esophagus. Circulating saline (5 L/min) was used to mimic blood flow along the LA and alteration of ionic content to modulate impedance. Thermistors along the region of interest were used to analyze temperature gradients. Varying time and power, radiofrequency (RF) ablation lesions were applied with an externally irrigated ablation catheter. Ablation strategies were divided into standard approaches (SAs, 10–15 g, 25–35 W, 30 s) or high‐power short duration (HPSD, 10–15 g, 40–50 W, 10 s). Temperature gradients, time to the maximum measured temperature, and the relationship between measured temperature as a function of distance from the site of ablation was analyzed.ResultsIn total, five experiments were conducted each utilizing new porcine posterior LA wall‐esophageal specimens for RF ablation (n = 60 lesions each for SA and HPSD). For both SA and HPSD, maximum temperature rise from baseline was markedly higher at the anterior wall (AW) of the esophagus compared to the esophageal lumen (SA: 4.29°C vs. 0.41°C, p < .0001 and HPSD: 3.13°C vs. 0.28°C, p < .0001). Across ablation strategies, the average temperature rise at the AW of the esophagus was significantly higher with SA relative to HPSD ablation (4.29°C vs. 3.13°C, p = .01). From the start of ablation, the average time to reach a maximum temperature as measured at the AW of the esophagus with SA was 36.49 ± 12.12 s, compared to 16.57 ± 4.54 s with HPSD ablation, p < .0001. Fit to a linear scale, a 0.37°C drop in temperature was seen for every 1 cm increase in distance from the site of ablation and thermistor location at the AW of the esophagus.ConclusionBoth SA and HPSD ablation strategies resulted in markedly higher temperatures measured at the AW of the esophagus compared to the esophageal lumen, raising concern about the value of clinical intraluminal temperature monitoring. The temperature rise at the AW was lower with HPSD. A significant time delay was seen to reach the maximum measured temperature and a modest increase in distance between the site of ablation and thermistor location impacted the accuracy of monitored temperatures.
Understanding neuronal gene expression changes induced by distal demyelination or inflammatory insult (BA6P.137)
Clarkson, Ben, Mirchia, Kanish , Kim, Hyo , LaFrance‐Corey, Reghann G., Howe, Charles W., Sauer, Brian, Howe, Charles

Mayo Clinic

The Journal of Immunology | December 30, 2022 | Volume: 194 | Issue: 1_Supplement | Pages: 114.18-114.18

10.4049/jimmunol.194.supp.114.18 Get It

Abstract MR imaging suggests an anatomic correspondence between WM and GM lesions in progressing MS patients, suggesting an underlying neuronal-signaling or neurodegenerative element to the progressive disease state. While retrograde signals evolving from stressed axons that alter soma gene expression have been previously described in models of axonal transection or crush injury, those resulting from inflammation and demyelination are unknown. Using microfluidic chambers that segregate neuronal soma and axons, we have previously demonstrated increased axonal MHC I following treatment with IFNg, a cytokine prominent in demyelinating MS lesions. Furthermore, expression of antigen-loaded MHC I predisposed axons to injury by antigen-specific CD8+ T cells in vitro. Here we report that neurons also upregulate expression of MHC class Ib mRNAs in response to axonal stimulation with IFNg. Genes most highly upregulated following cytokine treatment included H2-M3, H2-Q5, H2-Q6, H2-Q7, H2-Q8, H2-T10 , and H2-T23. We further report the development of an in vivo model system for measuring axonal vulnerability to antigen-specific immune attack following demyelination using an AAV vector to induce neuron-specific expression of axonally-targeted neoantigen (ovalbumin) tagged with cleavable eGFP. We also present optimized methods using AAV vectors in mice for infecting retinal, motor cortex, and hippocampal neurons to induce target gene expression in axons projecting to optic nerve and corpus collosum.
Advances in Cardiac Electrophysiology
Piccini, Jonathan P. , Russo, Andrea M. , Sharma, Parikshit S. , Kron, Jordana , Tzou, Wendy S. , Sauer, William H. , Park, David , Birgersdotter‐Green, Ulrika , Frankel, David S. , Healey, Jeff S. , Linz, Dominik , Wißner, Erik , Zeitler, Emily P. , Wang, Paul J. , Tzou, Wendy , Park, David S , Hummel, John , Koruth, Jacob , Linz, Dominik , Mittal, Suneet , Nair, Devi G , Nattel, Stanley , Noseworthy, Peter A , Steinberg, Benjamin A , Trayanova, Natalia A , Wan, Elaine Y , Wissner, Erik , Zeitler, Emily P , Wang, Paul J , Healey, Jeffrey S , Hummel, John D. , Noseworthy, Peter A. , Steinberg, Benjamin A. , Trayanova, Natalia A. , Wan, Elaine Y.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | November 28, 2022 | Volume: 15 | Issue: 12 | Pages: No page available

10.1161/circep.121.009911 | PMID 36441565 Get It

Despite the global COVID-19 pandemic, during the past 2 years, there have been numerous advances in our understanding of arrhythmia mechanisms and diagnosis and in new therapies. We increased our understanding of risk factors and mechanisms of atrial arrhythmias, the prediction of atrial arrhythmias, response to treatment, and outcomes using machine learning and artificial intelligence. There have been new technologies and techniques for atrial fibrillation ablation, including pulsed field ablation. There have been new randomized trials in atrial fibrillation ablation, giving insight about rhythm control, and long-term outcomes. There have been advances in our understanding of treatment of inherited disorders such as catecholaminergic polymorphic ventricular tachycardia. We have gained new insights into the recurrence of ventricular arrhythmias in the setting of various conditions such as myocarditis and inherited cardiomyopathic disorders. Novel computational approaches may help predict occurrence of ventricular arrhythmias and localize arrhythmias to guide ablation. There are further advances in our understanding of noninvasive radiotherapy. We have increased our understanding of the role of His bundle pacing and left bundle branch area pacing to maintain synchronous ventricular activation. There have also been significant advances in the defibrillators, cardiac resynchronization therapy, remote monitoring, and infection prevention. There have been advances in our understanding of the pathways and mechanisms involved in atrial and ventricular arrhythmogenesis.
Response to Rajendra
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Wani, Sachin , Falk, Gary W. , Yadlapati, Rena , Sauer, Bryan G.

Mayo Clinic

American Journal of Gastroenterology | November 3, 2022 | Volume: 117 | Issue: 11 | Pages: 1881-1882

10.14309/ajg.0000000000002012 | PMID 36327439 Get It

A Quality Improvement Project Aimed at Standardizing the Prescribing of Fluconazole Prophylaxis in a Level IV Neonatal Intensive Care Unit
Smith, Brandi, Rajapakse, Nipunie , Sauer, Hannah E. , Ellsworth, Kevin, Dinnes, Laura , Madigan, Theresa

Mayo Clinic

Pediatric Quality & Safety | July 19, 2022 | Volume: 7 | Issue: 4 | Pages: e579

10.1097/pq9.0000000000000579 | PMID 38585424 Get It

Introduction: Invasive candidiasis has a high morbidity and mortality among premature neonates. Antifungal prophylaxis with fluconazole significantly lowers the risk of invasive fungal infection in this population. We noted the use of fluconazole prophylaxis in our level IV neonatal intensive care unit (NICU) was variable and sought to standardize prescribing of prophylactic fluconazole. Methods: We formed a multidisciplinary team to develop an evidence-based protocol using literature and expert consensus to guide appropriate use of fluconazole prophylaxis in our level IV NICU. After determining baseline fluconazole prophylaxis prescribing before protocol implementation, we used plan-do-study-act (PDSA) cycles to introduce protocolized prescribing and incorporate it into daily practice. A 6-month intervention phase was followed by a 2-year control phase, in which monthly audits were performed to evaluate protocol adherence. Results were displayed in a statistical process control chart. Results: Before protocol implementation, fluconazole prophylaxis prescribing adhered to the protocol in 81% of patients. During the first PDSA cycle, adherence increased significantly to 94.5% (86/91 patients), which further increased to 98.7% (74/75 patients) during the second PDSA cycle and remained at 96% (120/125 patients) during the control phase (P < 0.0001). Conclusions: A multidisciplinary group-designed protocol was successful in standardizing fluconazole prophylaxis prescribing for infants in the level IV NICU. Adherence to protocol was high following implementation and was sustained for the duration of the project. There were no cases of invasive candidiasis noted.
Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020
Sauer, Adam , Daher, Ghazal S. , Lohse, Christine M. , Glasgow, Amy E. , Douse, Dontre’ M. , Moore, Eric J. , Ighodaro, Eseosa T. , Abel, Kathryn M. Van , Glasgow, Amy E. , Sauer, Adam B, Van Abel, Kathryn M , Glasgow, Amy E , Habermann, Elizabeth B. , Yin, Linda X.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | June 2, 2022 | Volume: 148 | Issue: 7 | Pages: 662

10.1001/jamaoto.2022.1028 | PMID 35653143 Get It

Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline
Shaheen, Nicholas J. , Iyer, Prasad G. , Souza, Rhonda F. , Sauer, Bryan G. , Wani, Sachin , Falk, Gary W. , Yadlapati, Rena

Mayo Clinic

American Journal of Gastroenterology | March 31, 2022 | Volume: 117 | Issue: 4 | Pages: 559-587

10.14309/ajg.0000000000001680 | PMID 35354777 Get It

Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly lethal cancer with an increasing incidence over the last 5 decades. These revised guidelines implement Grading of Recommendations, Assessment, Development, and Evaluation methodology to propose recommendations for the definition and diagnosis of BE, screening for BE and esophageal adenocarcinoma, surveillance of patients with known BE, and the medical and endoscopic treatment of BE and its associated early neoplasia. Important changes since the previous iteration of this guideline include a broadening of acceptable screening modalities for BE to include nonendoscopic methods, liberalized intervals for surveillance of short-segment BE, and volume criteria for endoscopic therapy centers for BE. We recommend endoscopic eradication therapy for patients with BE and high-grade dysplasia and those with BE and low-grade dysplasia. We propose structured surveillance intervals for patients with dysplastic BE after successful ablation based on the baseline degree of dysplasia. We could not make recommendations regarding chemoprevention or use of biomarkers in routine practice due to insufficient data.
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham, Neena S. , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Telford, Jennifer J , Barkun, Alan , Sauer, Bryan G. , Noseworthy, Peter A. , Leontiadis, Grigorios I.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 17, 2022 | Volume: 5 | Issue: 2 | Pages: 100-101

10.1093/jcag/gwac010 | PMID 35368325 Get It

AbstractWe conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1–7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y12 receptor inhibitor for patients on a single P2Y12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1–7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y12 receptor inhibitor drugs because of insufficient evidence.
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham, Neena S. , Barkun, Alan , Sauer, Bryan G. , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Telford, Jennifer J , Barkun, Alan N , Noseworthy, Peter A. , Leontiadis, Grigorios I.

Mayo Clinic

American Journal of Gastroenterology | March 17, 2022 | Volume: 117 | Issue: 4 | Pages: 542-558

10.14309/ajg.0000000000001627 | PMID 35297395 Get It

We conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1–7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y 12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y 12 receptor inhibitor for patients on a single P2Y 12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1–7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y 12 receptor inhibitor drugs because of insufficient evidence.
Transpharyngeal Approaches for Management of Oropharyngeal Squamous Cell Carcinoma: Mayo Clinic Institution Experience
Badaoui, Joseph N. , Sauer, Adam , Moore, Eric J. , Lohse, Christine M. , Kasperbauer, Jan L. , Noel, Daniel B., Olsen, Kerry D., Abel, Kathryn M. Van , Sauer, Adam B, Van Abel, Kathryn M , Yin, Linda X. , Price, Daniel L.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 18, 2022 | Volume: 167 | Issue: 3 | Pages: 509-516

10.1177/01945998211071000 | PMID 35041566 Get It

ObjectiveInvestigate oncologic and functional outcomes associated with transhyoid and lateral pharyngotomy (transpharyngeal) approaches in the treatment of oropharyngeal squamous cell carcinoma (OPSCC).Study DesignRetrospective review.SettingSingle institution (tertiary care center).MethodsThis is a retrospective case series of patients with OPSCC undergoing transpharyngeal resection from 1990 to 2017 at Mayo Clinic. Oncologic outcomes, postoperative complications, objective swallowing data, and rates of tracheostomy and percutaneous gastrostomy tube dependence were recorded.ResultsOf 83 patients meeting inclusion criteria, 56 (68%) were human papillomavirus positive. Overall survival rates at 5 and 10 years following surgery were 85% and 80%, respectively. Cancer‐specific survival rates at these same time points were 90% and 88%. Following treatment, 35 of 49 patients (71%) had a Functional Oral Intake Scale score ≥5, indicating total oral intake of multiple consistencies; 79 of 82 (96%) were without tracheostomy or laryngectomy; and 71 of 81 (88%) were on a full oral diet.ConclusionTranspharyngeal approaches provide adequate functional and oncologic outcomes in the majority of patients with OPSCC. These results may have important implications for patients who are not candidates for, or are unwilling to undergo, nonoperative therapy or for those without access to radiation therapy.